Literature DB >> 15765374

Update on detection of sentinel lymph nodes in patients with breast cancer.

John N Aarsvold1, Naomi P Alazraki.   

Abstract

Sentinel lymph node biopsy is now the practice of choice for the management of many patients with breast cancer. This was not true in the early 1990s, when the first such procedures were performed and protocols for such were refined often. This was also not true in the first years of the 21st century, when a decade of collective experience and information acquired from numerous clinical investigations dictated additional subtle and not-so-subtle refinements of the procedures. However, it is true today; reports of the latest round of clinical investigations indicate that there are several breast cancer sentinel node procedures that result in successful identification of potential sentinel nodes in nearly all patients who are eligible for such procedures. A significant component of many of these successful sentinel node procedures is a detection and localization protocol that involves radiotracer methodologies, including radiopharmaceutical administration, preoperative nuclear medicine imaging, and intraoperative gamma counting. The present state and roles of nuclear medicine protocols used in breast cancer sentinel lymph node biopsy procedures is reviewed with emphasis on discussion of recent results, unresolved issues, and future considerations. Included are brief reviews of present radiotracer and blue-dye techniques for node localization, including remarks about injection strategies, counting probe technology, and radiation safety. Included also are discussions of on-going investigations of the implications of the presence of micrometastases; of the management value of detection, localization, and excision of extra-axillary nodes such as internal mammary nodes; and of the broad range of recurrence rates presently being reported. Remarks on the present and possible near- and long-term roles for nuclear medicine in the staging of breast cancer patients including comments on positron emission tomography and intraoperative imaging conclude the article.

Entities:  

Mesh:

Year:  2005        PMID: 15765374     DOI: 10.1053/j.semnuclmed.2004.11.003

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  13 in total

1.  Hands-free, wireless goggles for near-infrared fluorescence and real-time image-guided surgery.

Authors:  Yang Liu; Adam Q Bauer; Walter J Akers; Gail Sudlow; Kexian Liang; Duanwen Shen; Mikhail Y Berezin; Joseph P Culver; Samuel Achilefu
Journal:  Surgery       Date:  2011-05       Impact factor: 3.982

2.  Hybrid 99mTc-magnetite tracer for dual modality sentinel lymph node mapping.

Authors:  Aidan Cousins; Chris Tsopelas; George Balalis; Sarah K Thompson; Dylan Bartholomeusz; A Bruce Wedding; Benjamin Thierry
Journal:  J Mater Sci Mater Med       Date:  2018-05-29       Impact factor: 3.896

3.  Clinical relevance of sentinel lymph nodes in the internal mammary chain in breast cancer patients.

Authors:  Pilar Paredes; Sergi Vidal-Sicart; Gabriel Zanón; Jaume Pahisa; Pedro Luís Fernández; Martín Velasco; Gorane Santamaría; Jaime Ortín; Joan Duch; Francesca Pons
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-09       Impact factor: 9.236

4.  Fluorescent LYVE-1 antibody to image dynamically lymphatic trafficking of cancer cells in vivo.

Authors:  Michele McElroy; Katsuhiro Hayashi; Barbara Garmy-Susini; Sharmeela Kaushal; Judith A Varner; A R Moossa; Robert M Hoffman; Michael Bouvet
Journal:  J Surg Res       Date:  2008-01-18       Impact factor: 2.192

5.  123I MIBG mapping with intraoperative gamma probe for recurrent neuroblastoma.

Authors:  Andrei Iagaru; David Peterson; Andrew Quon; Sanjeev Dutta; Claire Twist; Farhdad Daghighian; Sanjiv Sam Gambhir; Craig Albanese
Journal:  Mol Imaging Biol       Date:  2007-11-02       Impact factor: 3.488

6.  The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.

Authors:  Francesco Giammarile; Naomi Alazraki; John N Aarsvold; Riccardo A Audisio; Edwin Glass; Sandra F Grant; Jolanta Kunikowska; Marjut Leidenius; Valeria M Moncayo; Roger F Uren; Wim J G Oyen; Renato A Valdés Olmos; Sergi Vidal Sicart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-02       Impact factor: 9.236

7.  Imprint cytology predicts axillary node status in sentinel lymph node biopsy.

Authors:  Zarina Bell; Iain Cameron; J Stephen Dace
Journal:  Ulster Med J       Date:  2010-09

8.  Using the intraoperative hand held probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: a review of the literature.

Authors:  Suk Chul Kim; Dong Wook Kim; Renee M Moadel; Chun K Kim; Samprit Chatterjee; Michail K Shafir; Arlene Travis; Josef Machac; Borys R Krynyckyi
Journal:  World J Surg Oncol       Date:  2005-09-29       Impact factor: 2.754

9.  The sentinel node in breast cancer: an update.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

10.  Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.

Authors:  Shigeto Ueda; Hitoshi Tsuda; Hideki Asakawa; Jiro Omata; Kazuhiko Fukatsu; Nobuo Kondo; Tadaharu Kondo; Yukihiro Hama; Katsumi Tamura; Jiro Ishida; Yoshiyuki Abe; Hidetaka Mochizuki
Journal:  BMC Cancer       Date:  2008-06-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.